Skip to main content

Table 2 Patient clinical and epidemiological characteristics by HPV status, N = 346

From: NDN and CD1A are novel prognostic methylation markers in patients with head and neck squamous carcinomas

  

HPV (–)

HPV (+)

HPV (-)

HPV (+)

 

Characteristic

 

N

(%) among HPV(-)

N

(%) among HPV(+)

Mean (SD)

Mean (SD)

p-value

Age at Dx (years)

 

211

 

135

 

61.4 (12.3)

57.0 (9.6)

0.0002

Gender

Male

139

66 %

120

89 %

  

<0.0001

 

Female

72

34 %

15

11 %

   

Cancer Site

Larynx/Glottic

72

34 %

11

8 %

  

<0.0001

 

Oral Cavity

110

52 %

16

12 %

   
 

Oropharynx

20

9 %

105

78 %

   
 

Hypopharynx

9

4 %

3

2 %

   

Cancer Stage

I/Cis

36

17 %

11

8 %

  

<0.0001

 

II

28

13 %

7

5 %

   
 

III

39

18 %

13

10 %

   
 

IV

108

51 %

104

77 %

   

Comorbidities (ACE)

None

41

19 %

50

37 %

  

0.001

 

Mild

99

47 %

59

44 %

   
 

Moderate

50

24 %

20

15 %

   
 

Severe

21

10 %

6

4 %

   

Tobacco Use

Current (within past 12 months)

102

48 %

43

32 %

  

0.001

 

Former (quit > 12 months)

75

36 %

50

37 %

   
 

Never

34

16 %

42

31 %

   

Pack Years, n = 257

(cigs only)

    

38.4 (25.6)

29.9 (28.8)

0.02

Pack Years, n = 264

(cigs, cigars, pipe)

    

41.8 (34.5)

29.6 (29.4)

0.005

Alcohol Use, n = 244

Current (within past 12 months)

63

30 %

27

20 %

  

0.01

 

Former (quit > 12 months)

126

60 %

101

75 %

   
 

Never

22

10 %

7

5 %

   

Treatment, n = 335

Surg alone

53

26 %

14

11 %

  

<0.0001

 

Rad alone

23

11 %

11

8 %

   
 

Surg + Rad

30

15 %

4

3 %

   
 

Rad + Chemo

45

22 %

93

70 %

   
 

Surg + Rad + Chemo

29

14 %

10

8 %

   
 

No Treatment prior to death

22

11 %

1

1 %

   

Post Treatment Status

Free of Disease

186

88 %

131

97 %

  

0.004

 

Persistent Disease

25

12 %

4

3 %

   

KM estimate 2 year RPFT

  

69 %

 

84 %

  

0.001

KM estimate 2 year OST

  

71 %

 

91 %

  

<0.0001

  1. -Percentages will not add to 100 % horizontally. % presented is proportion of clinical or epidemiological subgroup among HPV status category. -p-values calculated by Wilcoxon-rank tests for continuous variables and Kruskal-Wallis tests for categorical variables. Log-rank test used for KM analysis